ZOETIS INC. (ZTS) — Analysis Summary
ZOETIS INC. (ZTS) has a market cap of $31.00B with year-over-year revenue growth of +2.3%. Net margin stands at 28.2%. The stock trades at a P/E ratio of 11.9.
Key Takeaways
- Revenue changed +2.3% year-over-year
- Net margin of 28.2%
- P/E ratio of 11.9
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, ZTS posted revenue growth of +2.3% and trades at a P/E of 11.9.
ZOETIS INC. (ZTS)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at 0.0x — earnings do not cover interest payments
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
14,500
Headquarters
PARSIPPANY, NJ
Exchange
XNYS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Annual Dividend/Share
$2.12
Dividend Yield
2.74%
Dividend History
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.